- Home
- ML vs CELC Comparison
ML vs CELC Comparison
Compare ML & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ML
- CELC
- Stock Information
- Founded
- ML 2013
- CELC 2011
- Country
- ML United States
- CELC United States
- Employees
- ML N/A
- CELC N/A
- Industry
- ML Retail: Computer Software & Peripheral Equipment
- CELC Medical Specialities
- Sector
- ML Technology
- CELC Health Care
- Exchange
- ML Nasdaq
- CELC Nasdaq
- Market Cap
- ML 482.3M
- CELC 489.7M
- IPO Year
- ML N/A
- CELC 2017
- Fundamental
- Price
- ML $86.52
- CELC $12.12
- Analyst Decision
- ML Buy
- CELC Strong Buy
- Analyst Count
- ML 7
- CELC 6
- Target Price
- ML $100.00
- CELC $29.17
- AVG Volume (30 Days)
- ML 329.6K
- CELC 228.8K
- Earning Date
- ML 11-07-2024
- CELC 11-14-2024
- Dividend Yield
- ML N/A
- CELC N/A
- EPS Growth
- ML N/A
- CELC N/A
- EPS
- ML 0.28
- CELC N/A
- Revenue
- ML $500,281,000.00
- CELC N/A
- Revenue This Year
- ML $30.87
- CELC N/A
- Revenue Next Year
- ML $23.59
- CELC N/A
- P/E Ratio
- ML $299.96
- CELC N/A
- Revenue Growth
- ML 23.40
- CELC N/A
- 52 Week Low
- ML $36.65
- CELC $11.51
- 52 Week High
- ML $106.82
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- ML 58.90
- CELC 34.34
- Support Level
- ML $85.75
- CELC $11.94
- Resistance Level
- ML $89.00
- CELC $13.14
- Average True Range (ATR)
- ML 3.79
- CELC 0.56
- MACD
- ML -1.29
- CELC 0.03
- Stochastic Oscillator
- ML 67.91
- CELC 12.68
About ML MoneyLion Inc.
MoneyLion Inc is a mobile banking and financial membership platform that empowers people to take control of their finances. It is a full-service digital platform to deliver mobile banking, lending, and investment solutions. The company offers a personalized, all-in-one, digital financial platform that provides convenient, low-cost access to banking, borrowing, and investing solutions tailored for its customers, rooted in data, and delivered through its proprietary technology platform.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.